Becton, dickinson and company:1106636 [16-031786]

Ended Awarded Last action

Contract number
HHSN26100021
Awardee
Awarding agency
Obligated
$13,243

Award facts

Opportunity
Contract value 100% obligated
$13,243.25 Current and potential, with all options
Completion date
Current and potential, with all options
Set-aside
No set-aside
Competition
Not Competed Only One Source
Pricing
Firm Fixed Price
Place of performance
Bethesda, MD 20892, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00001 · Reagents becton, dickinson and company:1106636 [16-031786] -$1,408
Original award $14,651

About this award

The National Cancer Institute issued a delivery order to Becton, Dickinson and Company on April 5, 2026, for flow cytometric analysis reagents with a ceiling value of $13,243.25.

Place of performance is Bethesda, MD 20892. The order has an ultimate completion date of April 5, 2026, and is priced as firm fixed price. No set-aside was used for this delivery order.

Quick answers

Who was awarded contract HHSN26100021?

HHSN26100021 was awarded to Becton, Dickinson And Company by National Cancer Institute (National Institutes of Health) on April 5, 2016.

How much is contract HHSN26100021 worth?

The government has obligated $13,243 on HHSN26100021.

Is contract HHSN26100021 an order under another contract?

Yes. HHSN26100021 is a delivery order under HHSN261201400013I, an indefinite delivery contract.

Was contract HHSN26100021 competed?

The extent of competition for HHSN26100021 was not competed.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award